2026-04-17T04:18:18Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/98262024-12-13T09:17:26Zcom_2072_378070com_2072_378040com_2072_378071col_2072_378092col_2072_378097

Liver transplantation in metastatic colorectal cancer: are we ready for it? Salvà, Francesc DOPAZO, CRISTINA López, Daniel Saoudi Gonzalez, Nadia Charco, Ramon Ros, Javier Baraibar, Iosune Tabernero, Josep Elez, Elena Fetge - Trasplantació Còlon - Càncer Recte - Càncer Metàstasi DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Digestive System Surgical Procedures::Surgical Procedures, Operative::Surgical Procedures, Operative::Liver Transplantation ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos del sistema digestivo::intervenciones quirúrgicas::intervenciones quirúrgicas::trasplante de hígado Liver transplantation; Metastatic colorectal cancer Trasplantament de fetge; Càncer colorectal metastàtic Trasplante de hígado; Cáncer colorrectal metastásico Colorectal cancer (CRC) is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Five-year overall survival remains modest among patients with metastatic CRC (mCRC) treated with conventional therapies however, liver transplantation in a highly selected population can improve clinical outcomes with an impressive 5-year overall survival of 83%. Despite liver transplantation appearing to be a promising therapeutical option for well-selected patients with mCRC with the liver-limited disease, these data come from small monocentric trials which included a heterogeneous population. Currently, several clinical trials are evaluating liver transplantation in this scenario, aiming for a more accurate patient selection by integrating liquid biopsy, tissue profiling, and nuclear medicine to the already known clinical biomarkers that eventually may lead to a survival improvement. In this paper, the clinical outcomes and inclusion criteria from the most relevant clinical trials and clinical series involving liver transplantation in patients with liver-limited disease colorectal cancer are reviewed as well as the trials currently recruiting. 2023-11-08T10:21:49Z 2023-11-08T10:21:49Z 2023-11-08T10:21:49Z 2023-06-21T07:36:10Z 2023-06-21T07:36:10Z 2023-05 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/9826 British Journal of Cancer;128 https://doi.org/10.1038/s41416-023-02213-1 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Springer Nature Scientia